Form 4: Amicus Therapeutics Acquired by BioMarin

Director Burke W. Whitman reports the disposal of all equity holdings following the acquisition of Amicus Therapeutics by BioMarin Pharmaceutical Inc.

Summary

• Burke W. Whitman, a Director at Amicus Therapeutics, disposed of 118,598 shares of common stock at $14.50 per share.
• Multiple tranches of stock options with exercise prices ranging from $5.96 to $12.81 were cancelled and converted into cash payments.
• The transactions were executed in connection with the completed acquisition of Amicus Therapeutics by BioMarin Pharmaceutical Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing documenting the final exit of a director following a completed corporate acquisition.

Positives

• The acquisition price of $14.50 per share provided liquidity for the director's holdings.
• All outstanding stock options held by the director were fully vested and converted into cash payments based on the merger consideration.

Negatives

• The director no longer holds any equity interest in Amicus Therapeutics following the completion of the merger.

Risks

• The company has been acquired and is no longer an independent publicly traded entity.

Future Outlook

The company has been acquired by BioMarin Pharmaceutical Inc., and the reporting person no longer maintains a position in the issuer.

Industry Context

StockSavvy.ai notes that this filing confirms the finalization of a significant M&A event in the biotechnology sector, reflecting ongoing consolidation trends where larger pharmaceutical entities acquire specialized firms to bolster their rare disease portfolios.

Comparison to Industry Standards

• The acquisition at $14.50 per share represents a standard exit event for directors following a definitive merger agreement.
• The conversion of unvested options into cash upon a change-in-control is consistent with standard executive compensation practices in biotech M&A.

Stakeholder Impact

• Shareholders have received the merger consideration of $14.50 per share.

Next Steps

• Finalization of all administrative requirements related to the merger.

Key Dates

Keywords

Amicus Therapeutics, BioMarin, Merger, Acquisition, FOLD, Form 4, Insider Transaction